search
Back to results

FOLFOXIRI Compared With FOLFIRI for Metastatic Colorectal Cancer

Primary Purpose

Metastatic Colorectal Cancer

Status
Completed
Phase
Phase 3
Locations
Italy
Study Type
Interventional
Intervention
FOLFIRI
FOLFOXIRI
Sponsored by
Gruppo Oncologico del Nord-Ovest
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Metastatic Colorectal Cancer focused on measuring Metastatic colorectal cancer, Phase III, FOLFOXIRI, FOLFIRI

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • adenocarcinoma of the colon or rectum
  • unresectable metastatic disease
  • age 18 to 75 years
  • Eastern Cooperative Oncology Group (ECOG) performance status of 2 or lower if age 70 years or younger or ECOG performance status of 0 if age 71 to 75 years measurable disease according to WHOcriteria
  • leukocyte count of at least 3,500/mm3, neutrophils count of at least 1,500/mm3, platelet count of at least 100,000/mm3
  • serum creatinine of 1.3 mg/dL or less
  • serum bilirubin less than 1.5 mg/dL and AST, ALT, and alkaline phosphatase 2.5 x normal values or less (</= 5 if liver metastases)
  • previous fluoropyrimidine-based adjuvant chemotherapy was allowed if ended more than 6 months before random assignment

Exclusion Criteria:

  • previous palliative chemotherapy for metastatic disease
  • previous chemotherapy including irinotecan or oxaliplatin
  • symptomatic cardiac disease, myocardial infarction in the last 24 months or uncontrolled arrhythmia
  • active infections
  • inflammatory bowel disease
  • total colectomy

Sites / Locations

  • Ospedale Civile Ss. Antonio E Biagio Di Alessandria - Alessandria (Al) Oncologia Medica
  • A.O. Universitaria Ospedali Riuniti - Ospedale Umberto I Di Ancona - Ancona (An) Oncologia Medica
  • Ausl Della Valle D' Aosta (Ao) - Aosta (Ao) Oncologia Medica
  • P.O. Zona Aretina - Ospedale S. Donato Di Arezzo - Arezzo (Ar) Oncologia Medica
  • Azienda Ospedale 'G.Rummo' - Benevento (Bn) Oncologia Medica
  • Ospedale Degli Infermi Di Biella - Biella (Bi) Oncologia Medica
  • Ospedale S. Orsola F.B.F. - Brescia - Brescia (Bs) Oncologia Medica
  • Stabilimento "Perrino" - Brindisi - Brindisi (Br) Oncologia Medica
  • Azienda Ospedaliera S. Elia - Caltanissetta (Cl) Oncologia Medica
  • Ospedale Versilia - Camaiore (Lu) Oncologia Medica
  • Ospedale Cecina - Cecina (Li) Oncologia Medica
  • Istituti Ospitalieri - Cremona - Cremona (Cr) Oncologia Medica
  • Azienda Ospedaliera S. Croce E Carle Di Cuneo - Cuneo (Cn) Oncologia Medica
  • Ausl 11 Di Empoli (Fi) - Empoli (Fi) Oncologia Medica
  • Asur - Zona Territoriale 6 Di Fabriano (An) - Fabriano (An) Oncologia Medica
  • Ospedale Santa Croce Fano - Fano (Pu) Oncologia Medica
  • Ausl 10 Di Firenze - Firenze (Fi) Oncologia Medica
  • A.O. Universitaria Careggi Di Firenze Oncologia Medica
  • E.O. Ospedali Galliera - Genova (Ge) Oncologia Medica
  • Irccs Istituto Nazionale Per La Ricerca Sul Cancro (Ist) - Genova (Ge) Oncologia Medica
  • Ospedale Sant'Andrea La Spezia - La Spezia (Sp) Oncologia Medica
  • Ausl Le Di Lecce - Lecce (Le) Oncologia Chirurgica
  • Ospedale Per Acuti "Mater Salutis" Legn. - Legnago (Vr) Oncologia Medica
  • U.O. Oncologia Medica, Ospedale Civile
  • Presidio Ospedaliero Piana Di Lucca - Lucca (Lu) Oncologia Medica
  • Irccs Fondazione Centro S. Raffaele Del Monte Tabor - Milano (Mi) Oncologia Medica
  • Ospedale Ca' Granda-Niguarda - Milano - Milano (Mi) Oncologia Medica
  • Ospedale Civile Di Mirano - Mirano (Ve) Oncologia Medica
  • A.O. Universitaria Federico Ii Di Napoli Oncologia Medica
  • A.O. Universitaria Maggiore Della Carita' Di Novara Oncologia Medica
  • A.O. Universitaria Di Parma Oncologia Medica
  • Asl 1 Di Citta' Di Castello (Pg) - Citta' Di Castello (Pg) Oncologia Medica
  • A.O. Di Perugia - Ospedale S. Maria Della Misericordia (Ex Silvestrini) - Perugia (Pg) Oncologia Medica
  • Azienda Ospedaliera San Salvatore - Pesaro (Pu) Oncologia Medica
  • Ospedale Piombino - Piombino (Li) Oncologia Medica
  • Ausl 5 Di Pisa - Pisa (Pi) Oncologia Medica
  • A.O. Universitaria Pisana - Pisa (Pi) Oncologia Medica
  • A.O. Universitaria Pisana Oncologia Medica
  • Ausl 3 Di Pistoia - Pistoia (Pt) Oncologia Medica
  • Ospedali Riuniti Di Pistoia - Pistoia (Pt) Oncologia Medica
  • Ospedale Di S. Maria Nuova - Reggio Nell'Emilia
  • Policlinico Universitario Campus Bio-Medico Di Roma Oncologia Medica
  • Policlinico Umberto I Di Roma Oncologia Medica
  • Policlinico Universitario Gemelli Di Roma Oncologia Medica
  • A.O. Universitaria Senese Oncologia Medica
  • Ausl 7 Di Siena - Siena (Si) Oncologia Medica
  • Ospedale Civile - Sondrio - Sondrio (So) Oncologia Medica
  • A.O. Universitaria S. Giovanni Battista-Molinette Di Torino Oncologia Medica

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

FOLFIRI

FOLFOXIRI

Arm Description

Irinotecan 180 mg/sqm on day 1 Leucovorin 100 mg/sqm on day 1 and day 2 5-fluorouracil 400 mg/sqm bolus followed by 5-fluorouracil 600 mg/sqm 22-hour continuous infusion on day 1 and day 2 Repeated every 2 weeks

Irinotecan 165 mg/sqm on day 1 Oxaliplatin 85 mg/sqm on day 1 Leucovorin 200 mg/sqm on day 1 5-fluorouracil 3200 mg/sqm 48-hour continuous infusion starting on day 1 Repeated every 2 weeks

Outcomes

Primary Outcome Measures

Response rate (RR)
Responses are evaluated every 8 weeks according to WHO criteria. The determination of responses and progression was initially based on investigator-reported measurements; computed tomography scans of all responding patients and of patients with stable disease were subsequently subjected to external review by an independent panel.

Secondary Outcome Measures

Progression-free survival (PFS)
PFS is defined as the length of time from random assignment to disease progression or to death resulting from any cause, whichever occurred first, or to last contact.
Overall survival (OS)
OS is defined as the length of time from random assignment to death or to last contact.
Postchemotherapy radical (R0) surgical resection rate of metastases
Percentage of patients who undergo radical (R0) resection of metastases after achieving objective response to chemotherapy.
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
During the full lenght of first-line treatment, number of enrolled patients reporting adverse events is recorded. Adverse events are evaluated according to National Cancer Institute Common Toxicity Criteria version 2.0.
Quality of life (QoL)
Quality of life is assessed at the beginning of each treatment cycle using the Quality of Life Questionnaire of the European Organisation for Research and Treatment of Cancer (version 2.0). The QLQ-C30 questionnaire was analyzed with the global health status/quality-of-life scale as the primary end point and the other 10 scales as secondary end points.

Full Information

First Posted
October 8, 2010
Last Updated
March 10, 2015
Sponsor
Gruppo Oncologico del Nord-Ovest
search

1. Study Identification

Unique Protocol Identification Number
NCT01219920
Brief Title
FOLFOXIRI Compared With FOLFIRI for Metastatic Colorectal Cancer
Official Title
Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) as First-line Treatment for Metastatic Colorectal Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
March 2015
Overall Recruitment Status
Completed
Study Start Date
November 2001 (undefined)
Primary Completion Date
November 2005 (Actual)
Study Completion Date
November 2009 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Gruppo Oncologico del Nord-Ovest

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of the study is to evaluate if the exposure to all the three active cytotoxic agents (FOLFOXIRI regimen) is superior in terms of response rate to conventional chemotherapy with the FOLFIRI regimen as first-line treatment of metastatic colorectal cancer patients.
Detailed Description
Survival of patients with metastatic colorectal cancer is correlated with the proportion of patients who receive all the three active drugs in the course of the disease, but not with the proportion of patients who receive any second-line therapy. In a sequential strategy, not all patients who progress after first-line chemotherapy are able to receive second-line treatment. Moreover, there is a correlation between the response rate to chemotherapy and the postchemotherapy radical resection rate of metastases. Therefore, a way to improve the outcome of metastatic colorectal cancer patients could be to administer a first-line regimen containing the three active agents.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Metastatic Colorectal Cancer
Keywords
Metastatic colorectal cancer, Phase III, FOLFOXIRI, FOLFIRI

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
244 (Actual)

8. Arms, Groups, and Interventions

Arm Title
FOLFIRI
Arm Type
Active Comparator
Arm Description
Irinotecan 180 mg/sqm on day 1 Leucovorin 100 mg/sqm on day 1 and day 2 5-fluorouracil 400 mg/sqm bolus followed by 5-fluorouracil 600 mg/sqm 22-hour continuous infusion on day 1 and day 2 Repeated every 2 weeks
Arm Title
FOLFOXIRI
Arm Type
Experimental
Arm Description
Irinotecan 165 mg/sqm on day 1 Oxaliplatin 85 mg/sqm on day 1 Leucovorin 200 mg/sqm on day 1 5-fluorouracil 3200 mg/sqm 48-hour continuous infusion starting on day 1 Repeated every 2 weeks
Intervention Type
Drug
Intervention Name(s)
FOLFIRI
Other Intervention Name(s)
Campto, l-lederfolin, 5-FU
Intervention Description
Irinotecan 180 mg/sqm on day 1 Leucovorin 100 mg/sqm on day 1 and day 2 5-fluorouracil 400 mg/sqm bolus followed by 5-fluorouracil 600 mg/sqm 22-hour continuous infusion on day 1 and day 2 Repeated every 2 weeks
Intervention Type
Drug
Intervention Name(s)
FOLFOXIRI
Other Intervention Name(s)
Campto, Eloxatin, l-leucovorin, 5FU
Intervention Description
Irinotecan 165 mg/sqm on day 1 Oxaliplatin 85 mg/sqm on day 1 Leucovorin 200 mg/sqm on day 1 5-fluorouracil 3200 mg/sqm 48-hour continuous infusion starting on day 1 Repeated every 2 weeks
Primary Outcome Measure Information:
Title
Response rate (RR)
Description
Responses are evaluated every 8 weeks according to WHO criteria. The determination of responses and progression was initially based on investigator-reported measurements; computed tomography scans of all responding patients and of patients with stable disease were subsequently subjected to external review by an independent panel.
Time Frame
Responses are evaluated every 8 weeks according to WHO criteria and reviewed by an independent panel at the end of treatment (6 months)
Secondary Outcome Measure Information:
Title
Progression-free survival (PFS)
Description
PFS is defined as the length of time from random assignment to disease progression or to death resulting from any cause, whichever occurred first, or to last contact.
Time Frame
Progressions are evaluated every 8 weeks according to WHO criteria and reviewed by an independent panel at the end of follow up (36 months)
Title
Overall survival (OS)
Description
OS is defined as the length of time from random assignment to death or to last contact.
Time Frame
For survival analysis participants are followed until death
Title
Postchemotherapy radical (R0) surgical resection rate of metastases
Description
Percentage of patients who undergo radical (R0) resection of metastases after achieving objective response to chemotherapy.
Time Frame
Postchemotherapy radical (R0) surgical resection rate of metastases were evaluated every 8 weeks during treatment and during follow up (36 months)
Title
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Description
During the full lenght of first-line treatment, number of enrolled patients reporting adverse events is recorded. Adverse events are evaluated according to National Cancer Institute Common Toxicity Criteria version 2.0.
Time Frame
Number of Participants with Adverse Events as a Measure of Safety and Tolerability were evaluated every 2 weeks during treatment and every 8 weeks during follow up (36 months)
Title
Quality of life (QoL)
Description
Quality of life is assessed at the beginning of each treatment cycle using the Quality of Life Questionnaire of the European Organisation for Research and Treatment of Cancer (version 2.0). The QLQ-C30 questionnaire was analyzed with the global health status/quality-of-life scale as the primary end point and the other 10 scales as secondary end points.
Time Frame
Quality of life was evaluated every 2 weeks during treatment and every 8 weeks during follow up (36 months)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: adenocarcinoma of the colon or rectum unresectable metastatic disease age 18 to 75 years Eastern Cooperative Oncology Group (ECOG) performance status of 2 or lower if age 70 years or younger or ECOG performance status of 0 if age 71 to 75 years measurable disease according to WHOcriteria leukocyte count of at least 3,500/mm3, neutrophils count of at least 1,500/mm3, platelet count of at least 100,000/mm3 serum creatinine of 1.3 mg/dL or less serum bilirubin less than 1.5 mg/dL and AST, ALT, and alkaline phosphatase 2.5 x normal values or less (</= 5 if liver metastases) previous fluoropyrimidine-based adjuvant chemotherapy was allowed if ended more than 6 months before random assignment Exclusion Criteria: previous palliative chemotherapy for metastatic disease previous chemotherapy including irinotecan or oxaliplatin symptomatic cardiac disease, myocardial infarction in the last 24 months or uncontrolled arrhythmia active infections inflammatory bowel disease total colectomy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alfredo Falcone, MD
Organizational Affiliation
University of Pisa
Official's Role
Principal Investigator
Facility Information:
Facility Name
Ospedale Civile Ss. Antonio E Biagio Di Alessandria - Alessandria (Al) Oncologia Medica
City
Alessandria
ZIP/Postal Code
15100
Country
Italy
Facility Name
A.O. Universitaria Ospedali Riuniti - Ospedale Umberto I Di Ancona - Ancona (An) Oncologia Medica
City
Ancona
ZIP/Postal Code
60100
Country
Italy
Facility Name
Ausl Della Valle D' Aosta (Ao) - Aosta (Ao) Oncologia Medica
City
Aosta
ZIP/Postal Code
11100
Country
Italy
Facility Name
P.O. Zona Aretina - Ospedale S. Donato Di Arezzo - Arezzo (Ar) Oncologia Medica
City
Arezzo
ZIP/Postal Code
52100
Country
Italy
Facility Name
Azienda Ospedale 'G.Rummo' - Benevento (Bn) Oncologia Medica
City
Benevento
ZIP/Postal Code
82100
Country
Italy
Facility Name
Ospedale Degli Infermi Di Biella - Biella (Bi) Oncologia Medica
City
Biella
ZIP/Postal Code
13900
Country
Italy
Facility Name
Ospedale S. Orsola F.B.F. - Brescia - Brescia (Bs) Oncologia Medica
City
Brescia
ZIP/Postal Code
25122
Country
Italy
Facility Name
Stabilimento "Perrino" - Brindisi - Brindisi (Br) Oncologia Medica
City
Brindisi
ZIP/Postal Code
72100
Country
Italy
Facility Name
Azienda Ospedaliera S. Elia - Caltanissetta (Cl) Oncologia Medica
City
Caltanissetta
ZIP/Postal Code
93100
Country
Italy
Facility Name
Ospedale Versilia - Camaiore (Lu) Oncologia Medica
City
Camaiore
ZIP/Postal Code
55043
Country
Italy
Facility Name
Ospedale Cecina - Cecina (Li) Oncologia Medica
City
Cecina
ZIP/Postal Code
57023
Country
Italy
Facility Name
Istituti Ospitalieri - Cremona - Cremona (Cr) Oncologia Medica
City
Cremona
ZIP/Postal Code
26100
Country
Italy
Facility Name
Azienda Ospedaliera S. Croce E Carle Di Cuneo - Cuneo (Cn) Oncologia Medica
City
Cuneo
ZIP/Postal Code
12100
Country
Italy
Facility Name
Ausl 11 Di Empoli (Fi) - Empoli (Fi) Oncologia Medica
City
Empoli
ZIP/Postal Code
50053
Country
Italy
Facility Name
Asur - Zona Territoriale 6 Di Fabriano (An) - Fabriano (An) Oncologia Medica
City
Fabriano
ZIP/Postal Code
60044
Country
Italy
Facility Name
Ospedale Santa Croce Fano - Fano (Pu) Oncologia Medica
City
Fano
ZIP/Postal Code
61032
Country
Italy
Facility Name
Ausl 10 Di Firenze - Firenze (Fi) Oncologia Medica
City
Firenze
ZIP/Postal Code
50122
Country
Italy
Facility Name
A.O. Universitaria Careggi Di Firenze Oncologia Medica
City
Firenze
ZIP/Postal Code
50134
Country
Italy
Facility Name
E.O. Ospedali Galliera - Genova (Ge) Oncologia Medica
City
Genova
ZIP/Postal Code
16128
Country
Italy
Facility Name
Irccs Istituto Nazionale Per La Ricerca Sul Cancro (Ist) - Genova (Ge) Oncologia Medica
City
Genova
ZIP/Postal Code
16132
Country
Italy
Facility Name
Ospedale Sant'Andrea La Spezia - La Spezia (Sp) Oncologia Medica
City
La Spezia
ZIP/Postal Code
19100
Country
Italy
Facility Name
Ausl Le Di Lecce - Lecce (Le) Oncologia Chirurgica
City
Lecce
ZIP/Postal Code
73100
Country
Italy
Facility Name
Ospedale Per Acuti "Mater Salutis" Legn. - Legnago (Vr) Oncologia Medica
City
Legnano
ZIP/Postal Code
37045
Country
Italy
Facility Name
U.O. Oncologia Medica, Ospedale Civile
City
Livorno
ZIP/Postal Code
57123
Country
Italy
Facility Name
Presidio Ospedaliero Piana Di Lucca - Lucca (Lu) Oncologia Medica
City
Lucca
ZIP/Postal Code
55100
Country
Italy
Facility Name
Irccs Fondazione Centro S. Raffaele Del Monte Tabor - Milano (Mi) Oncologia Medica
City
Milano
ZIP/Postal Code
20132
Country
Italy
Facility Name
Ospedale Ca' Granda-Niguarda - Milano - Milano (Mi) Oncologia Medica
City
Milano
ZIP/Postal Code
20162
Country
Italy
Facility Name
Ospedale Civile Di Mirano - Mirano (Ve) Oncologia Medica
City
Mirano
ZIP/Postal Code
30035
Country
Italy
Facility Name
A.O. Universitaria Federico Ii Di Napoli Oncologia Medica
City
Napoli
ZIP/Postal Code
80131
Country
Italy
Facility Name
A.O. Universitaria Maggiore Della Carita' Di Novara Oncologia Medica
City
Novara
ZIP/Postal Code
28100
Country
Italy
Facility Name
A.O. Universitaria Di Parma Oncologia Medica
City
Parma
ZIP/Postal Code
43100
Country
Italy
Facility Name
Asl 1 Di Citta' Di Castello (Pg) - Citta' Di Castello (Pg) Oncologia Medica
City
Perugia
ZIP/Postal Code
06012
Country
Italy
Facility Name
A.O. Di Perugia - Ospedale S. Maria Della Misericordia (Ex Silvestrini) - Perugia (Pg) Oncologia Medica
City
Perugia
ZIP/Postal Code
06156
Country
Italy
Facility Name
Azienda Ospedaliera San Salvatore - Pesaro (Pu) Oncologia Medica
City
Pesaro
ZIP/Postal Code
61100
Country
Italy
Facility Name
Ospedale Piombino - Piombino (Li) Oncologia Medica
City
Piombino
ZIP/Postal Code
57025
Country
Italy
Facility Name
Ausl 5 Di Pisa - Pisa (Pi) Oncologia Medica
City
Pisa
ZIP/Postal Code
56100
Country
Italy
Facility Name
A.O. Universitaria Pisana - Pisa (Pi) Oncologia Medica
City
Pisa
ZIP/Postal Code
56126
Country
Italy
Facility Name
A.O. Universitaria Pisana Oncologia Medica
City
Pisa
ZIP/Postal Code
56126
Country
Italy
Facility Name
Ausl 3 Di Pistoia - Pistoia (Pt) Oncologia Medica
City
Pistoia
ZIP/Postal Code
51100
Country
Italy
Facility Name
Ospedali Riuniti Di Pistoia - Pistoia (Pt) Oncologia Medica
City
Pistoia
ZIP/Postal Code
51100
Country
Italy
Facility Name
Ospedale Di S. Maria Nuova - Reggio Nell'Emilia
City
Reggio Emilia
ZIP/Postal Code
42100
Country
Italy
Facility Name
Policlinico Universitario Campus Bio-Medico Di Roma Oncologia Medica
City
Roma
ZIP/Postal Code
00128
Country
Italy
Facility Name
Policlinico Umberto I Di Roma Oncologia Medica
City
Roma
ZIP/Postal Code
00161
Country
Italy
Facility Name
Policlinico Universitario Gemelli Di Roma Oncologia Medica
City
Roma
ZIP/Postal Code
00168
Country
Italy
Facility Name
A.O. Universitaria Senese Oncologia Medica
City
Siena
ZIP/Postal Code
53100
Country
Italy
Facility Name
Ausl 7 Di Siena - Siena (Si) Oncologia Medica
City
Siena
ZIP/Postal Code
53100
Country
Italy
Facility Name
Ospedale Civile - Sondrio - Sondrio (So) Oncologia Medica
City
Sondrio
ZIP/Postal Code
23100
Country
Italy
Facility Name
A.O. Universitaria S. Giovanni Battista-Molinette Di Torino Oncologia Medica
City
Torino
ZIP/Postal Code
10134
Country
Italy

12. IPD Sharing Statement

Citations:
PubMed Identifier
17470860
Citation
Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crino L, Benedetti G, Evangelista W, Fanchini L, Cortesi E, Picone V, Vitello S, Chiara S, Granetto C, Porcile G, Fioretto L, Orlandini C, Andreuccetti M, Masi G; Gruppo Oncologico Nord Ovest. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007 May 1;25(13):1670-6. doi: 10.1200/JCO.2006.09.0928.
Results Reference
background
PubMed Identifier
18279572
Citation
Masi G, Vasile E, Loupakis F, Bursi S, Ricci S, Petrini I, Fontana A, Allegrini G, Falcone A. Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer. Clin Colorectal Cancer. 2008 Jan;7(1):7-14. doi: 10.3816/CCC.2008.n.002.
Results Reference
background
PubMed Identifier
19247029
Citation
Masi G, Loupakis F, Pollina L, Vasile E, Cupini S, Ricci S, Brunetti IM, Ferraldeschi R, Naso G, Filipponi F, Pietrabissa A, Goletti O, Baldi G, Fornaro L, Andreuccetti M, Falcone A. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg. 2009 Mar;249(3):420-5. doi: 10.1097/SLA.0b013e31819a0486.
Results Reference
background
PubMed Identifier
26861604
Citation
Cremolini C, Loupakis F, Masi G, Lonardi S, Granetto C, Mancini ML, Chiara S, Moretto R, Rossini D, Vitello S, Allegrini G, Tonini G, Bergamo F, Tomasello G, Ronzoni M, Buonadonna A, Bustreo S, Barbara C, Boni L, Falcone A. FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials. Ann Oncol. 2016 May;27(5):843-9. doi: 10.1093/annonc/mdw052. Epub 2016 Feb 9.
Results Reference
derived

Learn more about this trial

FOLFOXIRI Compared With FOLFIRI for Metastatic Colorectal Cancer

We'll reach out to this number within 24 hrs